Blue Ridge Cancer Care

The trials here

What the 12 trials at this site are about, from their registry records.

Conditions

• Gastric and oesophageal cancer3 trials
• Lung cancer2 trials
• Pancreatic cancer2 trials
• Prostate cancer2 trials
• Bladder cancer1 trial
• Childhood cancers1 trial
• Colorectal cancer1 trial
• Endometrial cancer1 trial
• Follicular lymphoma1 trial
• Head and neck cancer1 trial
• Metastatic breast cancer1 trial
• Multiple myeloma1 trial
• and 1 more

Phase

• Phase 38 trials
• Phase 23 trials

Status

• Completed3 trials
• Recruiting3 trials
• Active, not recruiting2 trials
• Terminated2 trials
• Not yet recruiting1 trial
• Withdrawn1 trial

Lead sponsor

• Hoffmann-La Roche3 trials
• Amgen1 trial
• Celgene1 trial
• Daiichi Sankyo1 trial
• GE Healthcare1 trial
• and 5 more

Running trials

• Recruiting

  This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

  NCT07028853· Phase 3· Pfizer· Source

• Recruiting

  A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

  NCT07164443· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

  NCT06911502· Phase 3· Celgene· Source

  Contact: Amanda Gillespie-Twardy, Site 0146

• Recruiting

  Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

  NCT06731478· Phase 3· Daiichi Sankyo· Source

• Active, not recruiting

  Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

  NCT05945823· Phase 2· Taiho Oncology, Inc.· Source

• Active, not recruiting

  A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)

  NCT03148418· Phase 3· Hoffmann-La Roche· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Prostate cancer2 recruiting
• Follicular lymphoma1 recruiting
• Gastric and oesophageal cancer1 recruiting

Closed trials

• Recruiting

  A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

  NCT06695845· Phase 2· Jazz Pharmaceuticals· Source

  Contact: Clinical Trial Disclosure & Transparency

• Terminated

  Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients

  NCT05068726· GE Healthcare· Source

• Completed

  Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).

  NCT04472429· Phase 3· Incyte Corporation· Source

• Completed

  Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

  NCT04191616· Phase 2· Amgen· Source

• Completed

  A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

  NCT04256421· Phase 3· Hoffmann-La Roche· Source

• Terminated

  A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck

  NCT03452137· Phase 3· Hoffmann-La Roche· Source